Recent Finacing
Recent Raise
Optina develops a Retinal Deep Phenotyping platform using non‑invasive retinal imaging and AI to assess brain health and systemic disease, advancing an awAIr™ amyloid test with FDA Breakthrough designation.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Optina.
